Results 241 to 250 of about 81,306 (284)
Some of the next articles are maybe not open access.
Clinical Pharmacokinetics, 2000
Oxaliplatin is the first clinically available diaminocyclohexane platinum coordination complex. The drug is non-cross-resistant with cisplatin or carboplatin and is one of the few active drugs against human colorectal cancer. Its cytotoxicity is synergistic with fluorouracil and folinic acid (leucovorin), the reference treatment for this disease.
F, Lévi +3 more
openaire +2 more sources
Oxaliplatin is the first clinically available diaminocyclohexane platinum coordination complex. The drug is non-cross-resistant with cisplatin or carboplatin and is one of the few active drugs against human colorectal cancer. Its cytotoxicity is synergistic with fluorouracil and folinic acid (leucovorin), the reference treatment for this disease.
F, Lévi +3 more
openaire +2 more sources
Reactions Weekly, 2005
Oxaliplatin (L-OHP) is a new third generation 1,2-DACH-platinum derivative. Pre-clinical studies from human cell lines suggested that L-OHP was efficacious in treating advanced or recurrent colorectal cancer. Furthermore, L-OHP and fluorouracil combination was shown to be synergistic both in experimental studies and in clinical trials.
openaire +3 more sources
Oxaliplatin (L-OHP) is a new third generation 1,2-DACH-platinum derivative. Pre-clinical studies from human cell lines suggested that L-OHP was efficacious in treating advanced or recurrent colorectal cancer. Furthermore, L-OHP and fluorouracil combination was shown to be synergistic both in experimental studies and in clinical trials.
openaire +3 more sources